Genomes and Genes
relapsing remitting multiple sclerosis
Summary: The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)
Publications265 found, 100 shown here
- European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian GlaG Comi
Department of Neuroscience, Scientific Institute Ospedale San Raffaele, University of Milan, Italy
Ann Neurol 49:290-7. 2001..randomized trials demonstrated that glatiramer acetate (GA) reduces relapse rates in patients with relapsing remitting multiple sclerosis (RRMS)...
- The relation between inflammation and neurodegeneration in multiple sclerosis brainsJosa M Frischer
Department of Neuroimmunology, Center for Brain Research, Medical University of Vienna, Spitalgasse 4, A 1090 Wien, Austria
Brain 132:1175-89. 2009..It further indicates that the disease processes of multiple sclerosis may die out in aged patients with long-standing disease...
- Axonal loss in normal-appearing white matter in a patient with acute MSC Bjartmar
Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, OH 44195, USA
Neurology 57:1248-52. 2001..Axonal number and appearance was normal in ascending sensory tracts. CONCLUSIONS: These studies confirm axonal degeneration in the absence of myelin loss as one histopathologic correlate to abnormal MR findings in patients with MS...
- Cytokine mRNA expression in patients with multiple sclerosis and fatiguePeter Flachenecker
Department of Neurology, Julius Maximilians University of Wurzburg, Josef Schneider Strasse 11, D 97080 Wurzburg, Germany
Mult Scler 10:165-9. 2004..Fatigue is one of the most common disabling symptoms in patients with multiple sclerosis (MS), but the putative role of proinflammatory cytokines remains to be elucidated...
- Secondary progressive multiple sclerosis: current knowledge and future challengesMarco Rovaris
Neuroimaging Research Unit, Scientific Institute and University Ospedale San Raffaele, Milan, Italy
Lancet Neurol 5:343-54. 2006....
- Defining interferon beta response status in multiple sclerosis patientsRichard A Rudick
Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, OH 44195, USA
Ann Neurol 56:548-55. 2004..MRI classification may facilitate rational therapeutic decisions, better clinical trial designs, and studies correlating biomarkers with therapeutic response...
- Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosisL K Fisniku
NMR Research Unit, Department of Neuroinflammation, Institute of Neurology, University College London, UK
Brain 131:808-17. 2008..001). The estimated rate of lesion growth over 20 years was 0.80 cm3/year in those who retained a relapsing remitting multiple sclerosis course, and 2...
- Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MSR Zivadinov
Department of Clinical Medicine and Neurology, University of Trieste, Italy
Neurology 57:1239-47. 2001..Furthermore, there are no data on the impact of IVMP on T1 black holes or whole-brain atrophy...
- Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosisMaja Eriksson
Institute of Clinical Neuroscience, Sahlgrenska University Hospital, Gothenburg, Sweden
Mult Scler 9:260-74. 2003..Predictors from this study could be used to refine historically controlled trials...
- Progressive multifocal leukoencephalopathy in a patient treated with natalizumabAnnette Langer-Gould
Department of Neurology, Stanford University School of Medicine, Stanford, Calif, USA
N Engl J Med 353:375-81. 2005..The patient was treated with systemic cytarabine, and two months later, his condition had improved...
- Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosisMikael Schwarz
Glycominds Ltd, Lod 71291, Israel
J Neurol Sci 244:59-68. 2006..0001). The present findings support further assessment of serum anti-Galpha4Galpha antibodies as a potential biomarker for MS, which may confirm disease diagnosis and aid in its management...
- Natalizumab plus interferon beta-1a for relapsing multiple sclerosisRichard A Rudick
Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
N Engl J Med 354:911-23. 2006..Despite interferon beta therapy, many patients have relapses. Natalizumab, an alpha4 integrin antagonist, appeared to be safe and effective alone and when added to interferon beta-1a in preliminary studies...
- The effect of immunomodulatory treatment on multiple sclerosis fatigueL M Metz
Department of Clinical Neurosciences, University of Calgary, Alberta, Canada
J Neurol Neurosurg Psychiatry 75:1045-7. 2004..To assess the effects of glatiramer acetate and beta interferon on fatigue in multiple sclerosis...
- Immunomodulatory effects of Vitamin D in multiple sclerosisJorge Correale
Raul Carrea Institute for Neurological Research, FLENI, Montaneses 2325, 1428 Buenos Aires, Argentina
Brain 132:1146-60. 2009..and thirty-two Hispanic patients with clinically definite multiple sclerosis were studied, 58 with relapsing remitting multiple sclerosis during remission, 34 during relapse and 40 primary progressive multiple sclerosis cases...
- Statins as immunomodulators: comparison with interferon-beta 1b in MSO Neuhaus
Department of Neurology, Multiple Sclerosis Research Group, Karl Franzens Universität, Graz, Austria
Neurology 59:990-7. 2002..In order to evaluate the potential role of statins as immunomodulators in MS, the authors studied their immunologic effects in vitro and compared them to interferon (IFN)beta-1b...
- Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic reviewAnnette Langer-Gould
Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA 94305, USA
Arch Neurol 63:1686-91. 2006..To identify clinical and demographic factors associated with long-term disability in patients with relapsing-remitting multiple sclerosis...
- Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell levelKoen Venken
Hasselt University, Biomedisch Onderzoeksinstituut and Transnationale Universiteit Limburg, School of Life Sciences, Diepenbeek, Belgium
Immunology 123:79-89. 2008..Our results also suggest that Tregs accumulate in the CSF of RR-MS patients, in an attempt to down-regulate local inflammation in the central nervous system...
- Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribineH Bartosik-Psujek
Department of Neurology, Medical University, Lublin, Poland
Acta Neurol Scand 109:390-2. 2004..The aim of the study was to evaluate the effects of immunosuppressive therapy on production of two proinflammatory chemokines--interleukin-8 (IL-8) and RANTES (regulated on activation, normal T cell expressed and secreted)...
- A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisChris H Polman
Vrije Universiteit Medical Center, Amsterdam, The Netherlands
N Engl J Med 354:899-910. 2006..Natalizumab is the first alpha4 integrin antagonist in a new class of selective adhesion-molecule inhibitors. We report the results of a two-year phase 3 trial of natalizumab in patients with relapsing multiple sclerosis...
- A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapsesP W O'Connor
University of Toronto, Ontario, Canada
Neurology 66:894-900. 2006..In this randomized, double-blind, placebo-controlled Phase II study, the authors examined the safety and efficacy of oral teriflunomide in multiple sclerosis (MS) with relapses...
- Natural history of multiple sclerosis: a unifying conceptChristian Confavreux
Service de Neurologie A, the European Database for Multiple Sclerosis EDMUS Coordinating Center and INSERM U 433, Hopital Neurologique, Lyon, France
Brain 129:606-16. 2006....
- Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosisG Birnbaum
MS Treatment and Research Center, Minneapolis Clinic of Neurology, 4225 Golden Valley Road, Golden Valley, MN 55422, USA
Neurology 71:1390-5. 2008..To explore whether high-dose atorvastatin can be administered safely to persons with relapsing-remitting multiple sclerosis (MS) taking thrice weekly, 44 microg dose subcutaneous interferon beta-1a...
- Oral fingolimod (FTY720) for relapsing multiple sclerosisLudwig Kappos
Department of Neurology, University Hospital, Basel, Switzerland
N Engl J Med 355:1124-40. 2006..Fingolimod (FTY720) is a new oral immunomodulating agent under evaluation for the treatment of relapsing multiple sclerosis...
- Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosisB K Kleinschmidt-Demasters
Department of Pathology, University of Colorado Health Sciences Center, Denver 80262, USA
N Engl J Med 353:369-74. 2005..There was extensive tissue destruction and cavitation in the left frontoparietal area, large numbers of bizarre astrocytes, and inclusion-bearing oligodendrocytes, which were positive for JC virus DNA on in situ hybridization...
- Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trialDaniel D Mikol
University of Michigan Medical Center, Ann Arbor, MI 48109 0316, USA
Lancet Neurol 7:903-14. 2008..Our aim in the REGARD (REbif vs Glatiramer Acetate in Relapsing MS Disease) study was to compare interferon beta-1a with glatiramer acetate in patients with RRMS...
- Natalizumab effects on immune cell responses in multiple sclerosisMasaaki Niino
Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Quebec, Canada
Ann Neurol 59:748-54. 2006..Our objective was to study in vivo biological effects of natalizumab on immune cell phenotype and function in multiple sclerosis (MS) patients...
- Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year dataK P Johnson
Maryland Center for MS, Baltimore, MD 21201, USA
Acta Neurol Scand 111:42-7. 2005..To assess the long-term effectiveness of continuous glatiramer acetate (GA) therapy in relapsing-remitting multiple sclerosis (RRMS)...
- Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosisJordi Rio
Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
Mult Scler 11:306-9. 2005....
- Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MSL Kappos
University of Basel, Basel, Switzerland
Neurology 67:944-53. 2006..c.) interferon (IFN) beta-1a in relapsing-remitting multiple sclerosis (RRMS)...
- Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1aPeter Joseph Jongen
MS4 Research Institute, Ubbergseweg 34, 6522 KJ, Nijmegen, The Netherlands
J Neurol 257:584-9. 2010In patients with relapsing remitting multiple sclerosis (RRMS), the effect of interferon-beta (INFb) on health-related quality of life (HR-QoL) is not firmly documented...
- Cortical demyelination and diffuse white matter injury in multiple sclerosisAlexandra Kutzelnigg
Center for Brain Research, Medical University of Vienna, Vienna, Austria
Brain 128:2705-12. 2005..With chronicity, diffuse inflammation accumulates throughout the whole brain, and is associated with slowly progressive axonal injury in the NAWM and cortical demyelination...
- Eight-year follow-up study of brain atrophy in patients with MSE Fisher
Whitaker Biomedical Imaging Laboratory, The Cleveland Clinic Foundation, OH 44195, USA
Neurology 59:1412-20. 2002..The specific goals of this study were to determine if brain atrophy is related to subsequent disability status and to identify MRI correlates of atrophy progression...
- The IgG subclass-specificities of anti-IFNbeta antibodies change with time and differ between the IFNbeta products in relapsing remitting multiple sclerosis patientsEbrima Gibbs
Neuro Immunology Laboratory, Department of Medicine, University of British Columbia, 2211 Wesbrook Mall, Vancouver, BC, Canada
J Neuroimmunol 190:146-50. 2007..This difference in the levels of IgG3 may help to clarify the differences in the overall pattern of development of anti-IFNbeta antibodies in IFNbeta-1a-and IFNbeta-1b-treated patients...
- Cerebral atrophy measurement in clinically isolated syndromes and relapsing remitting multiple sclerosis: a comparison of registration-based methodsValerie M Anderson
MS NMR Research Unit, University College London, Institute of Neurology, Queen Square, London, UK
J Neuroimaging 17:61-8. 2007....
- Evidence of early cortical atrophy in MS: relevance to white matter changes and disabilityN De Stefano
Institute of Neurological Sciences, University of Siena, Italy
Neurology 60:1157-62. 2003....
- Sleep disturbance and fatigue in mild relapsing remitting multiple sclerosis patients on chronic immunomodulant therapy: an actigraphic studyLaura Mendozzi
Multiple Sclerosis Rehabilitation Unit, Milan, Italy
Mult Scler 16:238-47. 2010..Poor sleep is common in MS and it contributes to fatigue. The beta interferons produce systemic effects which may not adapt and may induce fatigue...
- Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1bA B Rao
Laboratory of Diagnostic Radiology Research, Clinical Center, NIH, Bethesda, MD 20892, USA
Neurology 59:688-94. 2002..To determine the effect of IV methylprednisolone (IVMP) on brain fraction volume (BFV), contrast-enhancing (CE) lesions, and white matter lesion load (WMLL) in patients with relapsing-remitting MS treated for acute exacerbations...
- Alemtuzumab vs. interferon beta-1a in early multiple sclerosisAlasdair J Coles
N Engl J Med 359:1786-801. 2008..Alemtuzumab, a humanized monoclonal antibody that targets CD52 on lymphocytes and monocytes, may be an effective treatment for early multiple sclerosis...
- Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imagingLuca Massacesi
Department of Neurological and Psychiatric Sciences, University of Florence, Florence, Italy
Arch Neurol 62:1843-7. 2005..Azathioprine is an immunosuppressive agent that reduces relapse rates in patients with multiple sclerosis (MS), but its efficacy in suppressing new brain lesions has never been evaluated...
- Grey matter loss in relapsing-remitting multiple sclerosis: a voxel-based morphometry studyA Prinster
Biostructure and Bioimaging Institute, National Council for Research, Edificio 10, Via Pansini, 5, 80131 Napoli, Italy
Neuroimage 29:859-67. 2006..Our findings suggest that in RR-MS cortical GM reduction preferentially involves left fronto-temporal structures and deep GM, the latter correlating preferentially to global lesion load...
- 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre studyPaul O'Connor
St Michael s Hospital, Toronto, Canada
Lancet Neurol 8:889-97. 2009....
- Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosisN Putzki
Department of Neurology, University Hospital Essen, Essen, Germany
Eur J Neurol 16:424-6. 2009Natalizumab has been recommended for the treatment of patients with relapsing remitting multiple sclerosis with insufficient response to interferon-beta (IFN-beta) or glatiramer acetate (GA).
- Brain atrophy in clinically early relapsing-remitting multiple sclerosisD T Chard
NMR Research Unit, Department of Clinical Neurology, Institute of Neurology, University College London, UK
Brain 125:327-37. 2002..The lack of correlation between lesion load measures and WMF suggests that pathological changes in white matter may occur by mechanisms which are at least partly independent from overt lesion genesis in early multiple sclerosis...
- Spectroscopic axonal damage of the right locus coeruleus relates to selective attention impairment in early stage relapsing-remitting multiple sclerosisMarien Gadea
Area de Psicobiologia, Facultat de Psicologia, Universitat de Valencia, Avda Blasco Ibáñez 21, E 46010, Valencia, Spain
Brain 127:89-98. 2004..The use of both 1H-MRS and DL showed the connection between axonal damage at right locus coeruleus and auditive selective attention dysfunction in early-stage RRMS...
- [Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: a descriptive analysis of 100 consecutive patients]E Le Page
Service de Neurologie, Hopital Pontchaillou, Rennes
Rev Neurol (Paris) 162:185-94. 2006..We report an observational study of 100 aggressive relapsing remitting (RR) MS patients treated by induction therapy with MITOX and followed up to 5 years...
- Effect of interferon beta-1a on serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patients. One year follow-up resultsRana Karabudak
Hacettepe University, Faculty of Medicine, Department of Neurology, Neuroimmunology Unit, 06100 Ankara, Turkey
J Neurol 251:279-83. 2004..The MMP-9 levels showed no significant changes while TIMP-1 levels gradually and significantly increased during 3rd and 6th months of therapy compared with pretreatment levels...
- Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing-remitting multiple sclerosis: a quantitative MR spectroscopic imaging studyP Kapeller
NMR Research Unit, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK
J Neurol 248:131-8. 2001..This preliminary finding should be confirmed in a larger cohort, and follow-up studies are also needed to determine the prognostic and pathophysiological significance of these early changes...
- Elevated serum soluble vascular adhesion protein-1 (VAP-1) in patients with active relapsing remitting multiple sclerosisLaura Airas
Department of Neurology and MediCity Research Laboratory, University of Turku, PO Box 52, 20521Turku, Finland
J Neuroimmunol 177:132-5. 2006..388+/-102 ng/ml, p=0.0068). We propose that VAP-1 might participate in controlling leukocyte entry into inflamed brain...
- Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparisonMark S Freedman
Department of Medicine Neurology, University of Ottawa, Ottawa, Ontario, Canada
Eur Neurol 60:1-11. 2008..In the absence of head-to-head studies for all products used to treat RRMS, it still may be possible to compare treatment effects by applying evidence-based medicine principles...
- Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI studyJens Wuerfel
Institute of Neuroimmunology, Charite, Berlin, Germany
Brain 127:111-9. 2004..Our data indicate that inflammation is accompanied by altered local perfusion, which can be detected prior to permeability of the BBB...
- Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosisJ Smolders
School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands
Mult Scler 14:1220-4. 2008..We investigated the association between serum levels of 25(OH)D and 1,25-dihydroxyvitamin D (1,25(OH)2D), the biologically active metabolite, and clinical MS severity as expressed by EDSS-score and relapse rate...
- Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysisLaure Michel
INSERM U643, CHU Nantes, Institut de Transplantation et de Recherche en Transplantation ITERT, and Faculté de Médecine, Universite de Nantes, Nantes, France
J Clin Invest 118:3411-9. 2008..The decreased inhibitory function of unfractioned CD4+CD25high cells previously observed might be due to abnormal activation of CD127high T cells in patients with MS...
- Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosisR M Valenzuela
UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ, USA
Mult Scler 13:754-62. 2007..To determine whether glatiramer acetate (GA)-induced lymphoproliferation and IFN-gamma and IL-4 modulation correlate with the clinical response in multiple sclerosis (MS)...
- Natalizumab for multiple sclerosisRichard M Ransohoff
Neuroinflammation Research Center, Department of Neurosciences, Lerner Research Institute and Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, OH 44195, USA
N Engl J Med 356:2622-9. 2007
- Thymic export function and T cell homeostasis in patients with relapsing remitting multiple sclerosisAndreas Hug
Department of Neurology, University of Heidelberg, Heidelberg, Germany
J Immunol 171:432-7. 2003..Altogether, our findings suggest that an impaired thymic export function and, as a consequence, altered ability to maintain T cell homeostasis and immune tolerance may play an important pathogenic role in RRMS...
- Clinical characteristics of responders to interferon therapy for relapsing MSE Waubant
UCSF MS Center, San Francisco, CA 94117, USA
Neurology 61:184-9. 2003..To determine the proportion of patients with multiple sclerosis (MS) who respond to interferon-beta (IFNB) therapy and assess whether clinical characteristics differ in IFNB responders vs nonresponders...
- A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosisClaudia C Kaiser
Department of Anesthesiology, University of Illinois, Chicago, 60612, United States
J Neuroimmunol 211:124-30. 2009..These results show that pioglitazone was well tolerated in RRMS patients with indications of beneficial effects, warranting further trials to establish clinical efficacy...
- Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trialHillel Panitch
University of Vermont College of Medicine, Neurology Health Care Service, 1 South Prospect Street, Burlington, VT 05401, USA
J Neurol Sci 239:67-74. 2005..The development of antibodies to IFN was associated with reduced efficacy on MRI measures and fewer IFN-related adverse events, but did not have an impact on relapse outcomes...
- Increased IL-13 but not IL-5 production by CD4-positive T cells and CD8-positive T cells in multiple sclerosis during relapse phaseHirofumi Ochi
Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 812 8582, Fukuoka, Japan
J Neurol Sci 201:45-51. 2002..A distinct profile of IL-13 and IL-5 production by disease and by phase of MS suggests an active involvement of these type 2 cytokines in central nervous system (CNS) inflammation...
- Recombinant human interferon beta in relapsing-remitting multiple sclerosis: a review of the major clinical trialsM Chofflon
Policlinique de Neurologie, Hopital Cantonal Universitaire, Genève Switzerland
Eur J Neurol 7:369-80. 2000..Furthermore, as inflammatory brain lesions in MS have been shown to exhibit more extensive and early axonal damage than previously suspected, early treatment may be advisable in order to delay disease progression in RRMS...
- Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegenerationIsobel A Scarisbrick
Program for Molecular Neuroscience, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Biol Chem 389:739-45. 2008..These novel findings suggest that KLK1 and KLK6 may serve as serological markers of progressive MS and contribute directly to the development of neurological disability by promoting axonal injury and neuron cell death...
- Abnormal ERPs and high frequency bands power in multiple sclerosisM Vazquez-Marrufo
Psychobiology Lab, Department of Experimental Psychology, University of Seville, Seville, Spain
Int J Neurosci 118:27-38. 2008..The combined analysis of frequency and time domain suggested diverse phenomena that occurred in the MS patient group related with the EEG background or the motivational status...
- The clinical impact of interferon beta antibodies in relapsing-remitting MSPaola Perini
Multiple Sclerosis Centre First Neurology Clinic, Dept of Neurological and Psychiatrical Sciences, University of Padova, Via Giustiniani, 5, 35128 Padova, Italy
J Neurol 251:305-9. 2004..These findings demonstrate that high titers of both BAbs and NAbs reduce the clinical efficacy of IFNbeta in patients with RRMS, which is important for the long-term efficacy of these drugs...
- Regulatory T cell function correlates with serum 25-hydroxyvitamin D, but not with 1,25-dihydroxyvitamin D, parathyroid hormone and calcium levels in patients with relapsing remitting multiple sclerosisJoost Smolders
School for Mental Health and Neuroscience, Maastricht University Medical Center, PO Box 616, 6200MD Maastricht, The Netherlands
J Steroid Biochem Mol Biol 121:243-6. 2010..These results suggest that the serum levels of 1,25(OH)2D, PTH, and total calcium are not critically involved in the correlation between vitamin D status and T cell regulation...
- A placebo-controlled trial of oral cladribine for relapsing multiple sclerosisGavin Giovannoni
Queen Mary University London, the Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, London, United Kingdom
N Engl J Med 362:416-26. 2010..Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsing-remitting multiple sclerosis...
- A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosisDerek Soon
Department of Neuroinflammation, Institute of Neurology, Queen Square, London, WC1N 3BG, United Kingdom
J Neurol 254:306-14. 2007..12). There is evidence of a subtle BBB leakage within visibly non-enhancing lesions in RRMS that was not modified by alpha4 integrin blockade in this substudy cohort...
- In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjectsM Ramanathan
Department of Pharmaceutics, 543 Cooke Hall, State University of New York at Buffalo, 14260 1200, Buffalo, NY, USA
J Neuroimmunol 116:213-9. 2001..To use DNA arrays to identify differences in gene expression associated with relapsing-remitting (RR) MS...
- Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosisJürgen Haas
Division of Molecular Neuroimmunology, Department of Neurology, University of Heidelberg, Germany
Eur J Immunol 35:3343-52. 2005..The effect was persistent and not due to responder cell resistance or altered survival of Treg, suggesting that a defective immunoregulation of peripheral T cells mediated by (CD4+)CD25high T lymphocytes promotes CNS autoimmunity in MS...
- Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriolSamantha S Soldan
Department of Neurology, Reed Neurological Research Center, University of California School of Medicine, Los Angeles, CA 90095, USA
J Immunol 171:6267-74. 2003..In a pilot trial, oral estriol treatment of relapsing remitting multiple sclerosis patients caused significant decreases in enhancing lesions on brain magnetic resonance imaging...
- A subtype of multiple sclerosis defined by an activated immune defense programL G M van Baarsen
Department of Molecular Cell Biology and Immunology, VU Medical Center, Amsterdam, The Netherlands
Genes Immun 7:522-31. 2006....
- Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisoloneE L J Hoogervorst
Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
Mult Scler 8:415-9. 2002..Multiple sderosis (MS) patients develop varying degrees of cerebral atrophy, which may already begin at disease onset The purpose of this study is to examine the effect of steroid treatment on cerebral volume in MS patients...
- Voxel-based analysis of grey matter magnetization transfer ratio maps in early relapsing remitting multiple sclerosisB Audoin
NMR Research Unit, Institute of Neurology, University College London, London, UK
Mult Scler 13:483-9. 2007....
- New natural history of interferon-beta-treated relapsing multiple sclerosisMaria Trojano
Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy
Ann Neurol 61:300-6. 2007..To investigate the impact of interferon-beta (IFNbeta) on disease progression in relapsing-remitting multiple sclerosis patients...
- Localization of grey matter atrophy in early RRMS : A longitudinal studyBertrand Audoin
NMR Research Group, Institute of Neurology, Queen Square, London, UK
J Neurol 253:1495-501. 2006..This study suggests that early in the clinical course of RRMS, the thalamic atrophy is more consistently apparent than regional cortical atrophy...
- Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosisM Bieniek
NMR Research Unit, Institute of Neurology, University College London, London, UK
J Neurol Neurosurg Psychiatry 77:1036-9. 2006..An improved understanding of the causes of early progressive disability in primary progressive multiple sclerosis (PPMS) could provide mechanistic targets for therapeutic intervention...
- Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive diseaseJ Killestein
Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
Mult Scler 7:145-50. 2001....
- Oral simvastatin treatment in relapsing-remitting multiple sclerosisTimothy Vollmer
Barrow Neurological Institute, St Joseph s Hospital and Medical Center, Phoenix, AZ, USA
Lancet 363:1607-8. 2004..0001) and 41% (p=0.0018), respectively. Treatment was well tolerated. Oral simvastatin might inhibit inflammatory components of multiple sclerosis that lead to neurological disability...
- Seven-Tesla magnetic resonance imaging: new vision of microvascular abnormalities in multiple sclerosisYulin Ge
Department of Radiology, Center for Biomedical Imaging, New York University School of Medicine, 650 First Ave, Room 615, New York, NY 10016, USA
Arch Neurol 65:812-6. 2008..Ultrahigh-field (eg, 7-T) magnetic resonance imaging (MRI) has become a tool for assessing vascular involvement in MS lesions owing to markedly increased image resolution and susceptibility contrast of venous blood...
- Abnormal sensorimotor control, but intact force field adaptation, in multiple sclerosis subjects with no clinical disabilityMaura Casadio
Department of Informatics, Systems and Telematics and Research Centre for Neuroscience and Neuroengineering, University of Genoa, Via Opera Pia 13, Genoa 16145, Italy
Mult Scler 14:330-42. 2008..This indicates that early in the disease MS subjects have intact adaptive capabilities, but impaired movement execution...
- Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expressionKoen Venken
Biomedisch Onderzoeksinstituut and Transnationale Universiteit Limburg, School of Life Sciences, Hasselt University, Diepenbeek, Belgium
J Neurosci Res 83:1432-46. 2006..These data are the first to demonstrate differences in function and FOXP3 expression of CD4(+)CD25(+) T cells from patients with RR- and SP-MS...
- Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosisDarcy Cox
University of California, San Francisco, USA
J Neurosci Nurs 38:167-71. 2006..Nurses who are familiar with these tools have the opportunity to have a significant positive impact on patient comfort, confidence, and, ultimately, successful long-term adherence to disease-modifying medications...
- Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosisD T Chard
NMR Research Unit, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK
Brain 125:2342-52. 2002..The correlation of clinical impairment with a raised NAWM Ins may indicate that glial proliferation also relates to function at this stage of the disease...
- Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosisJack C Sipe
Associate Professor, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
Expert Rev Neurother 10:365-75. 2010..Assessments and conclusions will include a speculative 5-year outlook...
- Treatment with laquinimod reduces development of active MRI lesions in relapsing MSC Polman
Department of Neurology, VU Medical Centre, Amsterdam, The Netherlands
Neurology 64:987-91. 2005..The purpose of this study was to evaluate safety, tolerability, and efficacy on MRI lesions of two different doses of laquinimod compared with placebo in patients with relapsing MS...
- Impaired short-term motor learning in multiple sclerosis: evidence from virtual realityLetizia Leocani
Department of Neurology, Clinical Neurophysiology and Neurorehabilitation, University Vita Salute, Scientific Institute Hospital San Raffaele, Milan, Italy
Neurorehabil Neural Repair 21:273-8. 2007..The objective of this study was to investigate the usefulness of VR in the assessment of short-term motor learning in multiple sclerosis (MS)...
- Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosisJason Ramtahal
The Walton Centre for Neurology and Neurosurgery, Lower Lane, Liverpool L9 7LJ, UK
J Neurol 253:1160-4. 2006..Acetate appears a safe and effective option for continuing disease modification in patients with relapsing remitting multiple sclerosis treated with Mitoxantrone...
- Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosisM S A Deloire
EA 2966 Neurobiology of Myelin Disorders Laboratory, University Victor Segalen, Case 78, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
J Neurol Neurosurg Psychiatry 76:519-26. 2005....
- Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb studyLudwig Kappos
University Hospital Basel, Basel, Switzerland
Lancet 372:1463-72. 2008..Oral fumarate (BG00012) might have dual anti-inflammatory and neuroprotective effects. Our aim was to assess the efficacy and safety of BG00012 in patients with relapsing-remitting multiple sclerosis...
- Increasing cord atrophy in early relapsing-remitting multiple sclerosis: a 3 year studyW Rashid
MS NMR Research Unit, Department of Neuroinflammation, Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK
J Neurol Neurosurg Psychiatry 77:51-5. 2006..It is less clear how early it can be detected in relapsing-remitting (RR) MS, and whether early cord atrophy relates to the concurrent or future clinical course...
- Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosisFriedemann Paul
Cecilie Vogt Clinic for Neurology in the HELIOS Clinic Berlin Buch, Charité University Medicine Berlin and Max Delbrueck Center for Molecular Medicine, Berlin, Germany
PLoS ONE 3:e1928. 2008..Recent data from animal models of multiple sclerosis (MS) and from a pilot study indicated a possible beneficial impact of statins on MS...
- Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrationsFlorian Then Bergh
Section of Neurology, Max Planck Institut fur Psychiatrie, Munchen, Germany
BMC Neurol 6:19. 2006..Intermittent IV-MP, alone or with immunomodulators, has been suggested but insufficiently studied as a strategy to prevent relapses...
- A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patientsC C Ford
MIND Imaging Center, Albuquerque, NM, USA
Mult Scler 12:309-20. 2006A decade of continuous glatiramer acetate (GA) use by relapsing remitting multiple sclerosis (RRMS) patients was evaluated in this ongoing, prospective study, and the neurological status of 'Withdrawn' patients was assessed at a 10-year ..
- Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal studyRichard A Rudick
Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland, OH, USA
Ann Neurol 60:236-42. 2006..To evaluate the relation between T2 lesions and disease severity in relapsing-remitting multiple sclerosis (MS)...
- Improvement of hand dexterity following motor cortex rTMS in multiple sclerosis patients with cerebellar impairmentG Koch
Clinica Neurologica, Dipartimento di Neuroscienze, Universita Tor Vergata, Rome, Italy
Mult Scler 14:995-8. 2008..rTMS of the motor cortex may be a useful approach to treat cerebellar impairment in MS patients...
- Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: sample size estimatesValerie M Anderson
MS NMR Research Unit, University College London Institute of Neurology, Queen Square, London, WC1N 3BG, UK
J Neurol 254:1588-94. 2007....
- Emerging oral therapies for multiple sclerosisB A Cohen
Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
Int J Clin Pract 61:1922-30. 2007..Therefore, alternative MS treatments with less invasive routes of administration and new modes of action are needed to expand the current treatment repertoire, increase patient satisfaction and adherence, and thereby improve efficacy...
- The relationship among depression, subjective cognitive impairment, and neuropsychological performance in multiple sclerosisL Julian
University of California, San Francisco, CA, USA
Mult Scler 13:81-6. 2007..Furthermore, patients may be more accurate reporters of their cognitive impairment after successful treatment for depression, suggesting that depression decreases the accuracy of patient reported cognitive impairment...
- Longitudinal follow-up of "benign" multiple sclerosis at 20 yearsAna Luiza Sayao
Department of Medicine Neurology, University of British Columbia, Vancouver, BC, Canada
Neurology 68:496-500. 2007..To evaluate disease status after 20 years in a cohort defined as "benign multiple sclerosis (MS)" (Expanded Disability Status Scale [EDSS] score < or = 3) at 10 years from onset...
- Genomic effects of IFN-beta in multiple sclerosis patientsBianca Weinstock-Guttman
Jacobs Neurological Institute, Buffalo General Hospital, Buffalo, NY 14203, USA
J Immunol 171:2694-702. 2003..The findings demonstrate that IFN-beta treatment induces specific and time-dependent changes in multiple mRNAs in lymphocytes of multiple sclerosis patients that could provide a framework for rapid monitoring of the response to therapy...
- A systematic approach to analyse health-related quality of life in multiple sclerosis: the GEDMA studyJ M Morales-Gonzáles
Department of Research, Ministry of Labour and Social Affairs, Madrid, Spain
Mult Scler 10:47-54. 2004..To describe a holistic and comprehensive approach to the assessment of sufferer's perceptions of health-related quality of life (HRQoL) in a cohort of multiple sclerosis (MS) patients...
- A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosisR Zivadinov
Department of Clinical Medicine and Neurology, University of Trieste, Trieste, Italy
J Neurol Neurosurg Psychiatry 70:773-80. 2001....
- Autoimmunity Center of Excellence - RochesterR John Looney; Fiscal Year: 2013..B cell depletion using rituximab has been shown to be effective in rheumatoid arthritis and relapsing remitting multiple sclerosis. We believe that inhibition of B cell migration into target tissues is responsible for much of ..
- Mining the Multiple Sclerosis miRNome for Disease MarkersAmy E Lovett Racke; Fiscal Year: 2010..This study is designed to identify normally occurring microRNA that may be dysregulating, promoting autoimmunity. The data will enable us to identify new therapeutic targets and disease biomarkers for MS. ..
- A Controlled Trial of CBT for Multiple Sclerosis InflammationDavid I Daikh; Fiscal Year: 2010..We also wilt enhance our understanding of mechanisms by examining potential psychosocial, immune, and endocrine mediators of the relationship betweenSLEs and clinical and neuroimaging markers of MS inflammation. ..
- Regulation of B-catenin by RPTPB/Z in fetal human glial progenitorsCrystal R McClain; Fiscal Year: 2012..Therefore, this proposal aims to characterize a novel candidate, pleiotrophin, and its likely contribution to inhibiting glial progenitor differentiation in vitro and in vivo. ..
- Tr1-Specific Tolerance: a Novel Treatment of Multiple SclerosisKanneganti Murthy; Fiscal Year: 2012..These studies will use a combination of actively induced and transfer models of EAE employing myelin-specific 5B6 PLP139-151-specific TCR transgenic T cells. ..
- Immunomodulation of Relapsing Remitting Multiple Sclerosis by Gut ParasitesZsuzsanna Fabry; Fiscal Year: 2010..NMSS) to test the efficacy of Helminth-induced Immunomodulatory Therapy (HINT) in patients with relapsing remitting multiple sclerosis (RRMS). Helminth-therapy, using T...
- Characterization of Symptom Occurrence in Persons with Multiple SclerosisPamela K Newland; Fiscal Year: 2012..This study is part of a larger mentored training program which includes structured mentorship, coursework, and other training activities to facilitate Dr. Newland's development as an independent nurse researcher. ..
- The role of mast cells in relapsing-remitting EAEMargaret E Walker; Fiscal Year: 2013..This research specifically focuses on this most clinically relevant disease model for human MS in order to identify novel therapeutic targets. ..
- ORAL IFN ALPHA--BIOLOGICAL EFFECTS IN MULTIPLE SCLEROSISStaley Brod; Fiscal Year: 1999..Ingested IFN-alpha may provide superior efficacy and safety in comparison to parenteral administered Type-1 IFNs in RR-MS and other autoimmune diseases. ..
- ORAL TOLERANCE TO MYELIN ANTIGENS IN EAEHoward Weiner; Fiscal Year: 1993..relevance as there currently are ongoing trials at our institution treating patients with early relapsing remitting multiple sclerosis via oral tolerization to myelin antigens...
- The Role of Mast in a Model of Relapsing-Remitting Multiple SclerosisBLAYNE A SAYED; Fiscal Year: 2010..In this application, we will use an established model of relapsing-remitting multiple sclerosis to examine some of the potential mechanisms that underlie mast cell effects on a disease course. ..
- EXTRAMURAL RESEARCH FACILITIES IMPROVEMENT PROGRAM GCRCRichard Rudick; Fiscal Year: 2003..The expected outcome of this construction project will be a centralized facility to conduct innovative, collaborative clinical research protocols and train a new generation of physician scientists. ..
- Case/Cleveland Clinic Clinical Research Training Program (RMI)Richard Rudick; Fiscal Year: 2007..It will host a national conference on this theme during 2007 to exchange "lessons learned" and evaluate how NIH-sponsored programs are measuring up to this strategic goal. [unreadable] [unreadable]..
- Case/Cleveland Clinical Research Training Program (RMI)Richard Rudick; Fiscal Year: 2004..It will host a national conference on this theme during 2007 to exchange "lessons learned" and evaluate how NIH-sponsored programs are measuring up to this strategic goal. ..
- Physical Activity and Quality of Life in Multiple SclerosisRobert Motl; Fiscal Year: 2007..unreadable] [unreadable] [unreadable]..
- IN VIVO TREATMENT OF EAE WITH ANTI I-A ANTIBODIESLawrence Steinman; Fiscal Year: 2001..Aim 5 is to assess the possibility of using DNA vaccination against TCR Vb for treatment of EAE. It is hoped that these studies will provide the basis for future clinical trials in MS patients. ..
- PEPTIDE MEDIATED IMMUNOTHERAPY FOR AUTOIMMUNE DISEASELawrence Steinman; Fiscal Year: 2003..This work with APL may be applicable not only to MS, but to other autoimmune diseases including juvenile diabetes, rheumatoid arthritis, and inflammatory bowel disease. ..
- Large Scale Images of Gene Transcription in MS and EAELawrence Steinman; Fiscal Year: 2004..The discovery of the role of osteopontin, first identified in large scale profiles, exemplifies how this approach may help us to understand MS and to develop new therapies. ..
- Pregnancy and the Modulation of Multiple SclerosisAnnette Langer Gould; Fiscal Year: 2006..The search for the pregnancy-related factor or hormone responsible for the protective effect of pregnancy in MS may potentially lead to the development of novel treatments for MS and other Th1-driven autoimmune diseases. ..
- Brain Atrophy/Diffusion Tensor Study/Multiple SclerosisRobert Fox; Fiscal Year: 2008..Furthermore, these studies should help develop improved methods for evaluating new therapeutic strategies for neuroprotection and neuroregeneration. ..
- Diffusion Tensor Imaging of Wallerian Degeneration in MSKhader Hasan; Fiscal Year: 2009..This tool will also help in the fusion of multi-modal MRI data for a robust segmentation of the subregions of CC and 1C. The DTI measures, after accounting for the age and gender dependence will be correlated with the clinical measures. ..
- Using the Internet to Improve Patient's Self-Management of Chronic IllnessDeborah Miller; Fiscal Year: 2006..The utilization analysis will allow us to identify the incremental benefit of the comprehensive system compared to the secure system and to determine where there greatest savings in overall cost of care is gained. ..
- HSP60 ABNORMALITIES IN SCHIZOPHRENIASaud Sadiq; Fiscal Year: 2001..Molecular studies will involve genomic and cDNA cloning of hsp60 from peripheral and brain tissue. Epitope mapping will be done by ELISA using overlapping peptides spanning the entire normal human hsp60 sequence. ..
- Caveolin-1/lGF-IR Interactions in OligodendrocytesDaniel Mikol; Fiscal Year: 2004..Understanding the interplay between the IGF-IR and caveolin-1 and their control of OLG phenotype will provide insight into the molecular basis of myelination by OLGs and, hopefully, guide new treatments for MS. ..
- T cell activation requirement in autoimmune demyelinationMichael K Racke; Fiscal Year: 2010..In addition, we will examine the production of IL-17-producing T cells from patients with multiple sclerosis and determine whether the current immunomodulatory therapies affect secretion of this cytokine. ..
- HIV Neuroprotection WorkshopJoseph Berger; Fiscal Year: 2004..The proposed conference is the first of its kind to highlight neuroprotection in HIV CNS and PNS disorders. By coupling this meeting with the International Symposium on Neurovirology this synergy can be exploited. ..
- NEUROSCIENCE OF HIV CONFERENCEJoseph Berger; Fiscal Year: 2002..Dr. Brian Wigdahl, international co-chair of the ISNV, is a co-investigator on this grant. ..
- MR PREDICTORS OF RESPONSE TO HAART IN HIV DEMENTIAJoseph Berger; Fiscal Year: 2004..It will also open novel avenues for exploring the differential sensitivities of these pathways to HAART, and suggest unique therapeutic options. ..
- JCV Virus Expression in Oropharynx and HIVJoseph Berger; Fiscal Year: 2004..This line of investigation would add credence to an oropharyngeal mechanism of JCV transmission and may ultimately lead to the clinical identification of an acute illness attributable to this pathogen. ..
- MYELINATION--ASSEMBLY OF LIPIDS AND PROTEINSJOYCE BENJAMINS; Fiscal Year: 2003..abstract_text> ..
- Gender differences in immune responses in MSRichard Ransohoff; Fiscal Year: 2009....
- Novel Clinical and Ocular Imaging Outcomes with Long-Term Follow-Up in MSLaura Balcer; Fiscal Year: 2010..Aim 3: Determine how low-contrast letter acuity, RNFL thickness, and total macular volume impact vision specific and overall health-related quality of life (HRQOL) in longitudinal studies of MS and ON. ..
- Cellular Mechanisms for Oligodendrocyte MyelinationBruce D Trapp; Fiscal Year: 2010..Collectively, these studies should identify therapeutic targets that enhance remyelination and reduce the progression of neurological disability in MS patients. ..
- Assessment of Penile Autonomic InnervationClaire Yang; Fiscal Year: 2007..The ability to detect cavernous neuropathy is relevant to the evaluation of erectile dysfunction, as well as the development of disease-specific treatments for neurogenic erectile dysfunction. [unreadable] [unreadable]..
- ANNUAL MRI, MTR AND HMRSI IN HEALTHY CONTROLS AND PPMSStephen Hauser; Fiscal Year: 2001....
- Treatment of Autoimmune Disease by Costimulatory Signal*Samia Khoury; Fiscal Year: 2007..The data obtained from the clinical trials and the critical information from the basic science projects will be valuable in getting us closer to our goal of tolerance induction for autoimmune disease. ..
- HIGHER SPEED, FIELD & SPATIAL RESOLUTION BRAIN 3D 1H MRSOded Gonen; Fiscal Year: 2001..Since expensive, fast shielded-gradients are not intrinsically required, the proposed research will make multivoxel brain 1H MRS accessible to sites not yet equipped with them. ..
- Quantifying Radiation-Therapy Brain Injury With 1H-MRSOded Gonen; Fiscal Year: 2003..H2: That WBNAA is more sensitive than MMSE to detect neuronal injury consequences of WBRT. H3: That this neuronal injury may be transient, in part, and could resolve within several months after WBRT. ..
- Role and Mechanism of PDI-PDL Pathway in EAESamia Khoury; Fiscal Year: 2007..We will define the interactions between the PD1 pathway and other CD28 homologues (CD28, CTLA4, ICOS) in regulating EAE. ..
- Modulation of type I diabetes with NKT cellsLuc Van Kaer; Fiscal Year: 2006..These studies will provide a better understanding of the immunological mechanisms that result in autoimmunity, and may lead to the development of novel agents for treatment of type I diabetes and other autoimmune diseases. ..
- THE ROLE OF B CELLS IN EAE PATHOGENESISAnne Cross; Fiscal Year: 2004..Methods to alter in humans the number and function of B cells and Abs already exist, making our results potentially applicable to MS therapy. ..
- Visual Dysfunction and Quality of Life in MSLaura Balcer; Fiscal Year: 2003..This proposal will provide a crucial foundation for future studies of vision in MS that will involve longitudinal assessment. ..
- DNA Tolerizing Vaccine Therapy for Multiple SclerosisHideki Garren; Fiscal Year: 2002..S. FDA for the evaluation of a DNA tolerizing vaccine in a phase I clinical trial. ..
- Excerise, Aging, and Psychological FunctionEdward McAuley; Fiscal Year: 2003..As such, the proposed study represents a unique attempt to further understand the role played by physical activity in the psychological health of older Americans. ..
- PERSONS WITH DISABILITIES: QUALITY OF CARE/SERVICE USELisa Iezzoni; Fiscal Year: 2001..Given that roughly 49 million Americans have a disabling condition, addressing concerns about their quality of care is essential. ..
- IMMUNOREGULATORY EFFECTS OF ESTROGEN IN EAEHalina Offner; Fiscal Year: 2010..E2 in relapsing, chronic, and spontaneous models of EAE. These studies will clearly establish E2- and EE- dependent pathways of EAE protection and therapy that may have direct relevance for future clinical trials in MS patients. ..
- Design & Synthesis of Novel CNS-Active Oxytocin and Vasopressin Receptor LigandsEdward Roberts; Fiscal Year: 2010....
- ASSESSING THE PERFORMANCE OF ALTERNATIVE RISK ADJUSTERSLisa Iezzoni; Fiscal Year: 2001..abstract_text> ..
- Molecular Libraries Screening Centers Network (MLSCN)(RMI)Hugh Rosen; Fiscal Year: 2007..unreadable] [unreadable]..
- Longitudinal Assessment of Visual Function in MSLaura Balcer; Fiscal Year: 2007....
- S1P Receptor subtypes: Regulating lymphocyte traffickingHugh Rosen; Fiscal Year: 2008..These studies will yield an enhanced understanding of the basic mechanisms by which S1P receptor agonism induces clinically useful immunosuppression of potential use in autoimmunity. ..
- ENDOCANNABINOID BIOMARKERS OF OBESITY USING INTEGRATED GENOMICS AND METABOLOMICSJACK SIPE; Fiscal Year: 2008..unreadable] [unreadable] [unreadable]..
- A PHASE ll TRIAL OF RITUXAN IN MULTIPLE SCLEROSISDOROTHY CROSS; Fiscal Year: 2007..Parks and Naismith, and PI will be able to focus 30% more time on investigator-initiated trials and mentoring junior colleagues. ..
- Novel MRI and 1H-MRS markers in Primary Progressive MSMatilde Inglese; Fiscal Year: 2009..Letter of support: Prof. John DeLuca, consultant PHS 398 (Rev. 05/01) Page. Form Page 3 Use /2-inch MARGINS. Number pages consecutively at the bottom throughout the application. Do not use suffixes such as 3a, 3b. ..
- Serial Brain 3D 1H MR Spectroscopy in Multiple SclerosisOded Gonen; Fiscal Year: 2009....
- Depression, Cytokines, and Pancreatic CancerWilliam Breitbart; Fiscal Year: 2006..abstract_text> ..
- Fish oil & alpha lipoic acid in mild Alzheimer's diseaseLynne Shinto; Fiscal Year: 2004..Compliance of fish oil supplementation will be assessed by red blood cell membrane fatty acid analysis. ..
- FAAH GENE MUTATIONS: RISK FACTORS IN DRUG USE/ADDICTIONJACK SIPE; Fiscal Year: 2006..abstract_text> ..
- MRI T2 shortening ('blackT2') in multiple sclerosisRohit Bakshi; Fiscal Year: 2003..Alternatively, if iron accumulation is a disease epiphenomenon, then BT2 could be used as a noninvasive marker of brain degeneration. ..